Charles Explorer logo
🇬🇧

Treatment of knee cartilage by cultured stem cells and three dimensional scaffold: a phase I/IIa clinical trial

Publication at Faculty of Medicine in Pilsen, Second Faculty of Medicine |
2023

Abstract

PURPOSE: Damage of the knee cartilage is a common condition manifesting itself mainly by pain and/or swelling that may substantially reduce the quality of life while ultimately leading to osteoarthritis in affected patients. Here, we aimed to evaluate the safety and efficacy of cultured autologous bone marrow mesenchymal stem cells (BM-MSCs) attached to the 3D Chondrotissue(R) scaffold by autologous blood plasma coagulation (BiCure(R) ortho MSCp) in the treatment of knee cartilage defects.

METHODS: The primary endpoint of this phase I/IIa clinical trial was to evaluate the safety of the treatment. The secondary objective was to determine the short-to-medium-term therapeutic outcomes by standardized scoring questionnaires including Lysholm Knee Scoring Scale (Lysholm score), Knee Injury and Osteoarthritis Outcome Score (KOOS), and pain Visual Analogue Scale (VAS) systems and imaging (X-ray and magnetic resonance imaging, MRI).

A total of six patients were included and followed for 12 months after the surgery. RESULTS: BiCure(R) ortho MSCp was well tolerated with no adverse events associated with the investigational medicinal product.

Significant improvements were observed in Lysholm scores and KOOS while X-ray showed no deterioration of the arthritis and MRI revealed a persistent filling of the chondral defects by the implant. CONCLUSION: Overall, our data demonstrate the safety of the tested investigational medicinal product.

The function of the treated knee improved within one year after surgery in all enrolled patients. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: EudraCT No.: 2018-004,067-31; October 18 2018.